AIDS Research and Treatment / 2012 / Article / Tab 2

Research Article

Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders

Table 2

Factors related to undetectable HIV-RNA levels in cerebrospinal fluid (CSF) at logistic regression model adjusted for age, gender, HIV-transmission route, time on HAART before neurological diagnosis (more or less than 6 months), abnormal mental status, cerebral atrophy, and neurological disorder.

VariablesCrude OR (95% CI) 𝑃 -valueModel 1Model 2Model 3
Adjusted OR (95% CI) 𝑃 -valueAdjusted OR (95% CI) 𝑃 -valueAdjusted OR (95% CI) 𝑃 -value

Plasma HIV-RNA (log10 cp/mL)0.57 (0.47–0.69)<0.010.70 (0.51–0.95)0.0240.70 (0.51–0.96)0.0270.68 (0.51–0.91)0.009
CD4 at diagnosis 1.05 (0.97–1.14)0.2210.97 (0.86–1.10)0.6800.96 (0.85–1.09)0.5570.96 (0.86–1.08)0.473
(50 cells increase)        
Drugs at diagnosis        
 (i) AZT3.60 (1.83–7.08)<0.012.15 (0.51–9.04)0.295    
 (ii) DDI2.37 (0.93–6.04)0.0711.67 (0.37–7.65)0.508    
 (iii) D4T3.65 (1.95–6.83)<0.011.53 (0.41–5.65)0.527    
 (iv) 3TC4.53 (2.54–8.10)<0.011.62 (0.39–6.66)0.505    
 (v) ABV1.17 (0.32–4.25)0.8070.22 (0.03–1.68)0.144    
 (vi) NVP4.10 (1.37–12.28)0.0124.46 (1.03–19.32)0.045    
 (vii) EFV7.38 (3.21–16.95)<0.014.87 (1.16–20.54)0.031    
 (viii) IDV1.90 (0.58–6.17)0.2880.86 (0.16–4.50)0.856    
 (ix) IDV/r3.14 (0.73–14.49)0.1252.06 (0.31–13.58)0.454    
 (x) NFV1.66 (0.63–4.35)0.3020.68 (0.16–2.78)0.587    
 (xi) LPV/r2.21 (0.75–6.51)0.1521.10 (0.22–5.64)0.907    
Drug classes        
 (i) No ARV1.00   1.00   
 (ii) NNRTIs-based regimens14.32 (6.13–33.44)<0.01  12.46 (3.28–47.4)<0.001  
 (iii) PIs-based regimens3.50 (1.54–7.96)<0.01  2.48 (0.75–8.22)0.138  
 (iv) Boosted PIs-based regimens6.88 (2.42–19.52)<0.01  5.64 (1.31–24.25)0.020  
 (v) Only NRTIs3.22 (0.83–12.53)0.092  1.25 (0.09–17.10)0.866  
 (vi) PI + NNRTIs-based regimens7.07 (1.57–31.89)0.01  10.42 (1.59–68.46)0.015  
Number of neuroactive drugs        
 (i) 01.00     1.00 
 (ii) 11.68 (0.20–14.41)0.634    1.67 (0.16–17.82)0.673
 (iii) 26.50 (3.01–14.04)<0.01    4.11 (1.22–13.79)0.022
 (iv) 3-46.58 (3.32–13.05)<0.01    5.48 (1.94–15.48)0.001
Cognitive symptoms0.47 (0.27–0.83)<0.010.38 (0.16–0.90)0.0290.38 (0.16–0.88)0.0250.41 (0.18–0.95)0.038

OR: odds ratio; IVDU: intravenous drug users; MSM: men who have sex with men; AZT: zidovudine; DDI: didanosine; D4T: stavudine; 3TC: lamivudine; ABV: abacavir; NVP: nevirapine; EFV: efavirenz; IDV/r: indinavir/ritonavir; IDV: indinavir; NFV: nelfinavir; LPV/r: lopinavir/ritonavir; ARV: antiretroviral therapy; NNRTI: nonnucleoside reverse trascriptase inhibitors; PI: protease inhibitors; NRTI: nucleoside reverse trascriptase inhibitors; HAART: highly active antiretroviral therapy; HIVE: HIV encephalopathy; PML: progressive multifocal leucoencephalopathy; EUO: encephalopathies of unknown origin; TE: toxoplasmic encephalitis; PCNSL: primary central nervous system cerebral lymphoma; CM: cryptococcosis; TB: CNS tuberculosis/tubercular meningitis.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.